Dr. Reddy’s avoids pitfalls of Ranbaxy, Wockhardt by cutting workers out of production Read more: Dr. Reddy’s avoids pitfalls of Ranbaxy, Wockhardt by cutting workers out of production

New Drug Approvals

FDA pressure pushes Indian drugmakers to move away from relying predominantly on low-wage workers

June 9, 2014 | By Eric Palmer

The execs at Dr. Reddy’s Laboratories have taken notice as some of its competitors in India have run afoul of the FDA over loose manufacturing standards. The actions have meant banned plants and plummeting revenues for Ranbaxy Laboratories and Wockhardt. To avoid that fate, Dr. Reddy’s and some other Indian drugmakers have decided it is worth investing hundreds of millions of dollars for new plants and equipment in a country that has traditionally relied on cheap human labor.

Read more: Dr. Reddy’s avoids pitfalls of Ranbaxy, Wockhardt by cutting workers out of production – FiercePharma Manufacturinghttp://www.fiercepharmamanufacturing.com/story/dr-reddys-avoids-pitfalls-ranbaxy-wockhardt-cutting-workers-out-production/2014-06-09#ixzz34ItyhN28
Subscribe at FiercePharma Manufacturing

Anji Reddy founded Dr Reddy’s in 1984 with Rs.25 lakh in initial capital. Photo: Mint

View original post